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ABSTRACT 
Objective: The present work aimed at synthesis of process related impurities of valganciclovir by using gancyclovir or monobenzyl ganciclovir as 
starting material comprising the following steps. 
Methods: Selective hydrolysis, reaction with coupling reagent followed by hydrolysis under basic conditions and hydrogenolysis in the presence of catalyst.  
Results: The final synthesized compounds 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-(benzyloxy)propyl acetate 2, 2-((2-amino-6-oxo-1H-
purin-9(6H)-yl) methoxy)-3-hydroxy propyl acetate 3, 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) methoxy) propane-1,3-diylbis (2((benzyloxy)carbonyl) 
amino)-3-methylbutanoate) 6, and 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)propane-1,3-diylbis(2-amino-3-methylbutanoate) 7 were 
sucessfully characterized by using FT-IR, 1H NMR and LC-MS. 
Conclusion: The two processes related impurities (monoacetoxy ganciclovir, 3 and bis-valine ester of ganciclovir, 7) of valganciclovir hydrochloride 
were reported via the formation of key intermediates (acetoxy benzyl ganciclovir, 2 and bis-Cbz-valine ester of ganciclovir, 6)  
Keywords: Valganciclovir, Ganciclovir, Antiviral, Acyclic nucleosides 
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INTRODUCTION 
Over the past decades drugs have become an important part in 
human life to combat various diseases. Most of the drugs used in 
this modern era are purely synthetic which were completely 
different when compared to our ancient days. Nowadays it is quite 
clear that most of the drugs certainly possess various impurities 
either by chemical or microbial [1-3]. In an Active Pharmaceutical 
Ingredient (API), process related impurities may have significant 
impact on the safety and quality of the drug products. Presence of 
impurity in trace amounts in drug substance and drug product is 
inevitable [4-6]. Sometimes the effects generated by impurities 
can be teratogenic and mutagenic. It is therefore necessary to 
monitor the impurity profile of any API and control it during the 
manufacturing process [7]. Hence, API impurity and threshold 
values should comply with the limits set by ICH guidelines, 
according to this any impurity which are forming at a level of ≥ 
0.10 % should be identified, synthesized and characterized 
separately [8,9]. So in any API there is a necessity to monitor the 
impurity profile and control it during the production [10]. 
Valganciclovir hydrochloride available under the trade name Valcyte 
commonly used for the treatment of retinitis caused by 
Cytomegalovirus (CMV). It is generally a prodrug of ganciclovir usually 
prescribed in patients who have impaired immune systems and also 
have applications in the people recovering from single or multiorgan 
transplants. Valganciclovir hydrochloride has high degree of water 
solubility with a pKa of 7.6 [11-14]. It is very important to understand 
the implications of acids and bases on valganciclovir because a slight 
change in pH results in hydrolysis and isomerisation substantially 
contributing to poor bioavailability [15, 16]. 
In the USP monograph of valganciclovir hydrochloride several 
impurities have been listed. Impurities in valganciclovir 
hydrochloride must be controlled and identified due to regulatory 
requirement and toxicity concerns. Literature survey reveals that 
there are several methods available for the synthesis of 
valganciclovir hydrochloride [17-20] and only a little amount of 
work has been carried out regarding synthesis of process related 
impurities of valganciclovir hydrochloride [21]. Schaeffer et al., have 
reported an alternate route for the synthesis of valganciclovir 
hydrochloride by using ganciclovir as starting material where both 
the hydroxyl groups are condensed with Cbz-L-valine anhydride to 
form bis-Cbz-L-valine ester of ganciclovir. Further, this is subjected 
to partial hydrolysis with n-propyl amine in hexane to obtain Cbz-L-
valine ester of ganciclovir which is finally hydrogenated with 
palladium hydroxide on carbon and hydrogen in methanol in the 
presence of hydrochloric acid [22]. A number of patent applications 
have been published by scientists from Syntex Inc in which various 
derivatives of valganciclovir are obtained through coupling of N and 
O protected ganciclovir with Cbz or Boc protected L-valine followed 
by deprotection [23]. An alternative method has been described by 
the Rao and his team [24] for the synthesis of valganciclovir 
congeners by coupling mono O-acetyl protected ganciclovir with 
Cbz-L-valine followed by hydrogenolysis whereas Nestor and his 
coworkers have reported synthesis of valganciclovir congeners from 
guanine [25]. Katkam et al., have reported process for the 
preparation of valganciclovir and its salts. In this process partial 
hydrolysis of ganciclovir were carried out in presence of n-
propylamine [26]. Ramachandra et al., have reported a process for 
the preparation of valganciclovir by using triacetyl ganciclovir as 
starting material [27]. Chandra and his team reported Preparation of 
esters of ganciclovir derivatives and enantiomerically pure esters of 
derivatives [28]. Recently Sharma and his coworkers have filed a 
patent in which valganciclovir derivatives were prepared by partial 
hydrolysis of bis Cbz-L-valine ester of ganciclovir followed by 
deprotection [29]. 
In the present work, four valganciclovir hydrochloride process related 
impurities namely 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-
(benzyloxy)propylacetate 2 (acetoxy benzyl gancyclovir), 2-((2-amino-6-
oxo-1H-purin-9(6H)-yl)methoxy)-3-hydroxy propyl acetate 3 
(monoacetoxy ganciclovir), 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) 
methoxy) propane1,3-diylbis(2(((benzyloxy)carbonyl)amino)-3-
methylbutanoate) 6 (bis-cbz-L-valine ester of ganciclovir), 2-((2-amino-
6-oxo-1H-purin-9(6H)-yl) methoxy)propane-1,3-diylbis(2-amino-3-
methylbutanoate) 7 (bis-L-valine ester of ganciclovir) were synthesized 
by using monobenzyl ganciclovir and as starting materials [fig. 1]. 
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Fig. 1: Process related impurities of Valganciclovir 
hydrochloride 
 
MATERIALS AND METHODS 
Materials and Instruments 
Solvents and reagents were commercially sourced and used without 
further purification. Thin layer chromatography (TLC) was 
performed on preparative plates of silica gel. Visualization was made 
with iodine chamber. Column chromatography was performed by 
using silica gel (100-200 mesh). NMR spectra were recorded on a 
Bruker Advance II-300 MHz spectro meter using TMS as internal 
standard (chemical shifts δ in ppm). LC-MS spectra were recorded 
on a Varian Inc, USA, 410 Prostar Binary LC with 500 MS IT PDA 
detectors.  
Synthesis 
The synthetic schemes leading to key precursors 2, 6 and the target 
compounds 3 and 7 formation are illustrated in [fig. 2-3]. The target 
compound mono acetoxy ganciclovir 3, was prepared using 
monobenzyl ganciclovir as a starting material. Monobenzyl 
ganciclovir is condensed with acetic acid in N,N-dimethyl-formamide 
(DMF) in the presence of N,N'-dicyclohexylcarbodiimide (DCC) and 
4-dimethyl-amino pyridine (DMAP) to form acetoxy benzyl 
ganciclovir, which is benzyl protected monoacetoxy ganciclovir 2. 
Deprotection reaction to remove benzyl group in intermediate 2 was 
carried out in methanol in presence of hydrochloric acid using 
palladium hydroxide on carbon and hydrogen.  
The target compound (bis-L-valine ester of ganciclovir) 7, was 
synthesized by using ganciclovir as a starting material where both the 
hydroxyl groups were condensed with Cbz-L-valine, 5 in (DMF) in the 
presence of (DCC) and 4-dimethyl-amino pyridine (DMAP) to form bis-
Cbz-L-valine ester of ganciclovir intermediate, 6. This intermediate 6 
was then hydrogenated in methanol with palladium hydroxide on 
carbon and hydrogen in the presence of hydrochloric acid. 
General procedure for the synthesis of acetoxy benzyl 
ganciclovir, 2 
A solution of acetic acid (0.34 ml, 0.005 mol) in DMF (5 ml) was 
added to a solution of (DCC) (0.7 g, 0.003 mol). The reaction mixture 
was stirred at 0 ˚C for 30 min. Later the reaction was filtered and the 
filtrate was added drop wise to a mixture of 2-amino-9-(((1-
(benzyloxy)-3-hydroxypropan-2yl) oxy) methyl)-1H-Purin-6 (9H)-
one, 1 (0.86g, 0.0025 mol), (DMAP) (35 mg, 0.001 mol) at 25 ˚C 
which was stirred over a period of 15 h. After stirring water was 
added to the reaction mixture and the layers were separated. The 
solvent from the organic layer was evaporated and ether (10 ml) 
was added to the residue and stirred further for 1 h. The solid 
precipitate formed after stirring was collected and dried for 30 min 
to afford 2 as white solid. 
Fig. 2: Scheme for the synthesis of monoacetoxy ganciclovir, 3 
 
Fig. 3: Scheme for the synthesis of bis-L-valine ester of 
ganciclovir, 7 
  
General procedure for the synthesis of monoacetoxy ganciclovir, 3 
To a stirred solution of 2 (0.50 g, 0.0013 mol) in methanol 10 % Pd 
(OH)2 (0.10 g, 0.0026 mol) was added and followed by addition of 33 
% aqueous hydrochloric acid (0.5 ml). The resulting suspension was 
hydrogenated using autoclave at 4 kg/cm2 for about 3 h. The final 
reaction mixture was filtered through Celite and washed with 
methanol (6 ml). The solvent removed under vacuum and the 
residue was subjected to recrystallization using water: isopropanol 
(1:10) to afford 3 as white solid. 
General procedure for the synthesis of (bis-L-valine ester of 
Ganciclovir), 7 
To a stirred solution of ganciclovir 4 (0.30 g, 0.0012 mol) and Cbz-L-
valine, 5 (0.60 g, 0.0024 mol) in DMF a solution of (DCC) (0.61 g, 
0.003 mol) and (DMAP) (35 mg, 0.001 mol) was added at 25 ˚C and 
kept for stirring over a period of 12 h. After stirring water was 
added to the reaction mixture and the layers were separated. The 
solvent of the organic layer was evaporated and ether (10 ml) was 
added to the residue and stirred further for 1 h. The solid precipate 
formed after stirring was collected and dried for 30 min to afford 6. 
To the stirred solution of 6 (0.92 g, 0.0013 mol) in methanol 10 % 
Pd(OH)2 (0.10 g, 0.0026 mol) was added and followed by addition of 
33 % aqueous hydrochloric acid (0.5 ml). The resulting suspension 
was hydrogenated using autoclave at 4 kg/cm2 for about 3 h. The 
final reaction mixture was filtered through celite and washed with 
methanol (6 ml). The solvent removed under vacuum and the 
residue was subjected to recrystallization using water: isopropanol 
(1:10) to afford 7 as off-white solid. 
RESULTS AND DISCUSSION 
Arzeno et al. have reported a process for the preparation of 
monoacetoxy ganciclovir using triacetyl ganciclovir as a starting 
material. Triacetyl ganciclovir is subjected to selective hydrolysis with an 
amine. Further, this intermediate is coupled with Cbz-L-valine in 
presence of (DCC) in a solvent mixture of methylene chloride and (DMF) 
and hydrolysed under basic conditions and finally hydrogenated in the 
presence of Palladium on carbon and hydrogen in presence of 
hydrochloric acid (HCl) in ethanol to prepare valganciclovir [30]. In the 
present work monoacetoxy ganciclovir 3 was prepared using 
monobenzyl ganciclovir as a starting material.  
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The process related substances of valganciclovir hydrochloride 2, 3, 
6 and 7 were successfully synthesized and characterized. The 
structure of synthesized compound 2, was confirmed with 1H NMR 
spectra showing 21 protons in which 9 protons are aromatic 
(Supplement: fig: 1) and LC-MS further confirmed the molecular ion 
peak at 388.1 (M+1) (Supplement: fig: 2). The structure of 
synthesized compound 3, was confirmed with 1H NMR spectra 
showing 14 protons in which 4 protons are aromatic (Supplement: 
fig: 3) and LC-MS further confirmed the molecular ion peak at 296 
(M-1) (Supplement: fig: 4). The structure of the synthesized 
compound 6, was confirmed with 1H NMR spectra showing 43 
protons in which 16 protons are aromatic (Supplement: fig: 5) and 
LC-MS further confirmed the molecular ion peak at 721 (M+1) 
(Supplement: fig: 6). The structure of compound 7, was confirmed 
with 1H NMR spectra showing 31 protons in which 4 protons are 
aromatic (Supplement: fig: 7) and LC-MS further confirms the 
molecular ion peak at 453 (M+1) (Supplement: fig: 8).  
Characterization 
Compound 2: C18H21N5 O5, yield: 79 %, IR (KBr, Vmax cm-1): 1697 (O-
C=O), 1635 (N-C=O), 1599 (C=N) (Supplement: Fig: 9). 1H NMR: (300 
MHz, DMSO-d6) δ 1.86(s,3H,-CO-CH3), 3.29-3.50(m,2H,-CH-CH2-O), 
3.91-4.10(m,3H,-O-CH-CH2-OCO-), 4.45(s,2H,-O-CH2-C6H5), 5.44 
(s,2H,N-CH2-O), 6.50(s,2H,NH2), 7.24-7.37(m,5H,-CH2-C6H5), 7.28 
(s,1H,-N-CH-N), 10.64(s,1H,-NH). LC-MS (m/z): 388.1 [M+1]. 
Compound 3: C11H14N5O5, yield: 82 %, IR (KBr, Vmax cm-1): 3500-
3100 (N-H), 3400 (O-H) 1624.0 (Amide C=O), 1633.8 (C=N) 
(Supplement: Fig: 10). 1H NMR: (300 MHz, DMSO-d6) δ 1.85(s,3H,-
CO-CH3), 3.35-3.44 (m,2H,-CH-CH2-O), 3.78-4.09(m,3H,-O-CH-CH2-
OCO-), 4.85(t,1H,-CH2-OH), 5.44 (s,2H,N-(CH)2-O), 6.49 (s,2H,NH2), 
7.81(s,1H,N-CH-N), 10.62 (s, 1H,-NH). LC-MS (m/z): 296 [M-1]. 
Compound 6: C35H43N7O10, yield: 85 %, IR (KBr, Vmax cm-1): 1100 (C-
O), 1680-1630 (Amide C=O), 1730 (Ester C=O) (Supplement: Fig: 
11). 1H NMR: (300 MHz, DMSO-d6) δ 0.82(s,12H,2 x-CH-(CH3)2), 
1.92(s,2H,2 x-CH-(CH3)2, 3.87-3.92(m,2H,-CO-2 x CH-CH-(CH3)2, 
4.03-4.24(m,5H,-O-CH-CH2-CH2-O),5.03(s, 4H, 2 x O-CH2-C6H5), 
5.43(s,2H,N-CH2-O), 6.49(s,2H,NH2), 7.30-7.35(m,10H, 2 x CH2C6H5, 
7.65-7.69 (m, 2H, 2 x NH-COO), 7.81(s,1H,-N-CH\-N), 10.65(s,1H,-
NH). LC-MS (m/z): 721 [M+1]. 
Compound 7: C19H31N7O6, yield: 76 %, IR (KBr, Vmax cm-1): 3500-
3100 (N-H) 1597 (Amide C=O), 1100 (C-O) (Supplements: Fig: 12). 
1H NMR: (300 MHz, DMSO-d6) δ 0.74-0.83(m, 12H, 2 x-CH-(CH3)2, 
1.67-1.73 (m, 2H, 2 x-CH-(CH3)2, 2.99-3.05 (m, 2H,2 x CH-CH(CH3)2, 
4.02-4.19(m,5H,-CH-CH2-CH2), 5.43(s,2H,N-CH2-O), 6.57(bs,2H, NH-
CH-NH2), 7.81(s,1H,-N-CH-N). LC-MS (m/z): 453 [M+1]. 
CONCLUSION 
Two process related impurities (monoacetoxy ganciclovir, 3 and bis-L-
valine ester of ganciclovir, 7) of valganciclovir hydrochloride were 
reported via the formation of key intermediates (acetoxy benzyl 
gancyclovir, 2 and bis-Cbz-L-valine ester of ganciclovir, 6) using 
synthetic schemes. These impurities were characterized by IR, NMR and 
LC-MS to confirm the presence of functional groups in their respective 
position. The developed synthetic scheme is reliable, economic and the 
synthesized impurities could be used as reference standards in analytical 
method validation of valganciclovir hydrochloride.  
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